EMD Serono, Inc. and Fast Forward, LLC Announce First Results of Their Collaboration to Advance Drug Development in Multiple Sclerosis

ROCKLAND, Mass. & NEW YORK--(BUSINESS WIRE)--EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt Germany, and Fast Forward, LLC, a not-for-profit organization established by the National Multiple Sclerosis Society to accelerate the development of discoveries into new or improved therapies, today announced the first four recipients of funding designed to speed research advances in mutually selected high potential areas of MS research. The awards total nearly $1.5 million. Two are allocated to development programs which are available to for-profit entities and two are allocated to innovation projects, available to university-based investigators and seed-stage for-profit entities. EMD Serono and Fast Forward are currently soliciting proposals (Request for Proposals - RFPs) for the next round of funding available through this collaboration. (For more information please visit: www.nationalmssociety.org/fast-forward/index.aspx)